Slingshot Insights

Catalyst

Slingshot members are tracking this event:

OPKO to Present Long-acting Human Growth Hormone (hGH-CTP) Phase 2 Pediatric Growth Hormone Deficiency Data at the 55th Annual Meeting of the European Society for Paediatric Endocrinology

Source Link:: http://investor.opko.com/releasedetail.cfm?ReleaseID=987849

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

OPK

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Optimal Sampling of IGF-1 During Weekly Administration of a Long Acting Human Growth Hormone (MOD 4023)

http://abstracts.eur...

Additional Relevant Details Efficacy of Once-Weekly Administration of CTP-Modified Human Growth Hormone (MOD-4023): 24-Month Complete Database Results of a Phase 2 Study in Children with Growth Hormone Deficiency

http://abstracts.eur...

Additional Relevant Details Safety and Tolerability of Once-Weekly Administration of CTP-Modified Human Growth Hormone (MOD-4023): 24-month Complete Dataset Results of a Phase 2 Study in Children with Growth Hormone Deficiency

http://abstracts.eur...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Sep 12, 2016

Occurred Source:

http://abstracts.eurospe.org/hrp/0086/hrp0086RFC8.3.htm

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords European Society For Paediatric Endocrinology, Human Growth Hormone, Hgh-ctp